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INTRODUCTION
Bone metastasis is present in 20-30% of patients at the
initial diagnosis of lung cancer (1-3). Evaluating metastatic
bone lesions is important in determining the therapeutic plan.
Bone scan (BS) and serum alkaline phosphatase (ALP) concen-
tration are used to diagnose bone metastasis in malignancy
(4, 5). Although BS is sensitive in detecting advanced meta-
static bone lesions, its specificity is less than optimal because
infection, trauma, arthropathy, and neoplasm also may increase
radionuclide uptake (6).
Whole-body fluoro-D-glucose positron emission tomog-
raphy (FDG PET) and positron emission tomography com-
puted tomography (PET/CT) are being used increasingly,
especially for node staging (3). Several studies of PET and
metastatic bone lesion have been reported (7, 8). PET is as
accurate as BS in detecting metastatic bone lesions and has
better specificity than BS, but there are few studies of bone
metastases using PET/CT. The purpose of this study was to
compare the usefulness of whole-body FDG PET/CT, BS, and
serum ALP concentration in detecting bone metastases in
patients with newly diagnosed lung cancer, and to find the role
of BS in a new era of PET/CT.
MATERIALS AND METHODS
Study patients
The electronic medical record database at Seoul National
University Hospital was reviewed retrospectively to identify
all patients seen between January 2004 and December 2005
with a new diagnosis of lung cancer. Lung cancer in all pati-
ents was confirmed pathologically, and patients underwent
both whole-body 2-deoxy-2-
18F-fluoro-D-glucose (
18F-FDG)
PET/CT and BS for staging evaluation. Serum ALP concen-
tration was measured within five days of the PET/CT scan in
all patients. The PET/CT scan, BS, and measurement of ALP
concentration were completed before initiation of therapy
and after sufficient (six months or more) follow up. The study
protocol was submitted to and approved by an internal review
boards.
275
Joo-Won Min, Sang-Won Um, 
Jae-Jun Yim, Chul-Gyu Yoo, 
Sung Koo Han, Young-Soo Shim, 
and Young Whan Kim
Division of Pulmonary and Critical Care Medicine,
Department of Internal Medicine, and Lung Institute of
Medical Research Center, Seoul National University
College of Medicine, Seoul, Korea
Address for correspondence
Young Whan Kim, M.D.
Department of Internal Medicine, Seoul National 
University Hospital, 28 Yeongeon-dong, Jongno-gu,
Seoul 110-774, Korea
Tel : +82.2-2072-2856, Fax : +82.2-762-9662
E-mail : ywkim@snu.ac.kr
J Korean Med Sci 2009; 24: 275-80
ISSN 1011-8934
DOI: 10.3346/jkms.2009.24.2.275
Copyright � The Korean Academy
of Medical Sciences
The Role of Whole-Body FDG PET/CT, Tc 99m MDP Bone 
Scintigraphy, and Serum Alkaline Phosphatase in Detecting Bone
Metastasis in Patients with Newly Diagnosed Lung Cancer
Bone scan (BS) and serum alkaline phosphatase (ALP) concentration are used to
detect bone metastasis in malignancy, although whole-body fluoro-D-glucose posi-
tron emission tomography computed tomography (FDG PET/CT) is being used
increasingly. But BS is still used for the detection of metastatic bone lesion. So we
compared the usefulness of PET/CT, BS, and serum ALP in detecting bone metas-
tases in patients with newly diagnosed lung cancer. The medical record database
was queried to identify all patients with a new diagnosis of lung cancer between
January 2004 and December 2005, who had a PET/CT, BS, and serum ALP before
treatment. We retrospectively reviewed all patients’ records and radiological reports.
One hundred eighty-two patients met the inclusion criteria. Bone metastases were
confirmed in 30 patients. The sensitivity values were 93.3% for PET/CT, 93.3% for
BS, 26.7% for serum ALP concentration, and 26.7% for BS complemented with
serum ALP concentration. The respective specificity values were 94.1%, 44.1%,
94.1%, and 97.3%. The kappa statistic suggested a poor agreement among the
three modalities. FDG PET/CT and BS had similar sensitivity, but PET/CT had
better specificity and accuracy than BS. PET/CT is more useful than BS for evalu-
ating bone metastasis. However, in the advanced stage, because of its high speci-
ficity, BS complemented with serum ALP is a cost-effective modality to avoid hav-
ing to use PET/CT.
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PET/CT studies were performed using a combined PET/CT
scanner (Philips Gemini, DA best, Netherlands). PET/CT
images were acquired 1 hr after injection of 0.14 mCi/kg of
18F-FDG in the 3 dimension mode, from the skull to the mid-
thigh, at 7-9 bed positions of 2.5 min each. CT images were
used for attenuation correction and fusion; no contrast medi-
um was used. Helical CT was acquired first with the follow-
ing parameters: 50 mAs, 120 kV, 5 mm section thickness,
and 0.75 sec per CT rotation. The CT data were resized from
a 512×512 matrix to a 144×144 matrix to match the PET/
CT data to fuse the images.
Bone scan
BS was performed by the intravenous administration of
technetium-99m methylene diphosphonate at a dose of 35-
40 mCi. Images were obtained after 3 hr on a gamma cam-
era (E.CAM, Siemens, Erlangen, Germany).
Interpretation of nuclear imaging
Two or three experienced nuclear medicine physicians inter-
preted the PET/CT studies and BS as positive for bone metas-
tasis if they contained a focal increased uptake area.
Measurement of serum ALP concentration
Serum ALP concentration was measured with a Hitachi
747 autoanalyzer (Hitachi-Roche, Tokyo, Japan) using p-
nitrophenyl phosphatase as the substrate. The reference range
for serum ALP concentration was 30-115 IU/L in our insti-
tute. All values higher than the reference range were consid-
ered as positive for bone metastasis.
Confirmation of bone metastases
Bone metastases were confirmed using the following cri-
teria: 1) progressing bone lesion on the follow-up scan (PET/
CT or BS); 2) confirmed bone metastasis by simple radiog-
raphy, CT, or magnetic resonance imaging (MRI); 3) posi-
tive initial findings on both BS and PET/CT in the same
bone lesion with symptoms; and 4) histological confirma-
tion. In a patient with clinical evidence of infection, trauma,
or arthropathy, the results were classified as negative for bone
metastasis even though scan results suggested the presence
of metastasis. When the PET/CT and BS results were dis-
cordant, symptoms and additional results of plain radiogra-
phy, CT, and MRI were considered. In patients with a posi-
tive PET/CT or BS, we reviewed the follow-up records six
months or longer after the initial PET/CT scan, except for
patients who had died. The average follow-up interval was
333 days. Patients who showed no evidence suggesting bone
metastasis during the follow-up period were classified as hav-
ing no bone metastasis.
Statistical analyses
The sensitivity, specificity, accuracy, positive predictive
value, negative predictive value, and agreement between each
modality were calculated. To evaluate the independent con-
tributions of PET/CT, BS, and serum ALP concentration in
predicting bone metastasis, the kappa (κ ) statistic was calculat-
ed to determine the agreement between variables. The κ value
was categorized as follows: poor (<0.30), good (0.31-0.60),
and excellent (0.61-1.0). The detection of bone metastasis by
PET/CT, BS, and serum ALP concentration were compared
using the McNemar test; p<0.05 was considered significant.
The mean serum ALP concentrations were compared between
the ‘with bone metastasis group’ and the ‘without bone metas-
tasis group’ using a t test. SPSS (version 12.0) and STATA
(version 8.0) programs were used for statistical analysis.
RESULTS
Characteristics of patients
We identified 182 patients eligible for analysis who met
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Miscellaneous: adenoid cystic carcinoma, adenosquamous carcino-
ma, carcinoid, pleomorphic carcinoma, bronchoalveolar carcinoma,
poorly differentiated carcinoma.
NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.
Stage N (%)
N (%) Cell type
Table 1. Stage distribution and histological type of the study
population
NSCLC
Stage I 32 (17.6)
Stage II 12 (6.6)
Stage III 75 (41.2)
Stage IV 49 (26.9)
Total 168
SCLC
Limitted stage 7 (3.8)
Extensive stage 7 (3.8)
Total 14 (7.7)
Total 182
NSCLC
Adenocarcinoma 73 (40.1)
Squamous cell carcinoma 58 (31.9)
Large cell carcinoma 4 (2.2)
NSCLC, undetermined 27 (14.8)
Miscellaneous 6 (3.3)
SCLC 14 (7.7)
Total 182the inclusion criteria and who had sufficient follow-up peri-
ods. One hundred thirty-six were men, and 46 were women.
The mean age of the patients was 61.8±10.4 yr. The aver-
age interval between PET/CT and BS was 8.5±14.0 days.
The stage distribution and pathologic diagnosis of patients
are given in Table 1. Forty-nine patients had stage 4 nons-
mall cell lung cancer (NSCLC), and seven patients had exten-
sive stage small cell lung cancer (SCLC).
PET/CT
The PET/CT had 93.3% sensitivity, 94.1% specificity,
75.5% positive predictive value, 98.6% negative predictive
value, and 93.4% accuracy (Table 4).
True positives
Thirty-seven patients had a positive PET/CT; 28 of these
patients were confirmed with osseous metastasis.
Twenty six of 28 patients had bone metastasis with a pos-
itive bone scan finding. Bone metastasis was confirmed by
MRI in 17 patients. Four patients had definite bone pain that
could be explained only by bone metastasis. Three patients
were confirmed by simple roentgenography, one patient by
chest CT, and another patient by follow-up bone scan 131
days after the initial BS (Table 2).
Two patients of 28 patients had bone metastasis with a
negative BS finding. One had left-side scapular pain (PET/
CT-positive lesion) and a follow-up BS 102 days after the
initial scan revealed progression of bone metastasis (its max-
imal standardised uptake value [SUV] was 3.2). Metastasis
was confirmed in another patient as T-spine metastasis by
spine MRI 122 days after the PET/CT scan (maximal SUV:
3.8). 
False positives
Nine patients with a positive PET/CT finding were con-
firmed not to have bone metastasis.
Seven patients with positive PET/CT and bone scan find-
ings were confirmed as having no bone metastasis by check-
ing the MRI (one patient), follow-up BS (three patients), fol-
low-up PET/CT (one patient), and definite trauma history
(two patients).
Two patients with positive PET/CT and negative BS find-
ings had no symptoms, and plain radiography did not iden-
tify any bony abnormality to suggest bone metastasis. In these
patients, there was no evidence of bone metastasis during the
follow up.
False negatives
Two patients had positive results only in the BS (negative
PET/CT results). One patient was confirmed to have bone
metastasis by spine MRI at the initial staging evaluation.
Another patient with positive BS findings on the spine had
no symptoms, and this patient received a lobectomy (T2N0)
without further evaluation. After the operation, the patient
developed back pain, and simple roentgenography revealed
bone metastasis progression.
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In many patients, metastatic bone lesions were confirmed by two or
more confirmation criteria.
PET/CT, positron emission tomography computed tomography; MRI,
magnetic resonance imaging. 
Confirmation criteria Number of patients
Progressing bone lesion on follow-up scan  2
(PET/CT or bone scan)
Confirmed bone metastasis by simple radiography,  22
CT, or MRI
Positive initial findings on both bone scan and  5
PET/CT in the same bone lesion with symptoms
Histological confirmation 1
Total 30
Table 2. Confirmation of bone metastasis
Final diagnosis
PET/CT
Total
PET/CT findings
Positive Negative
Metastatic 28 2 30
Benign 9 143 152
Total 37 145 182
Final diagnosis
Bone scan
Total
PET/CT findings
Positive Negative
Metastatic 28 2 30
Benign 85 67 152
Total 113 69 182
Table 3. Distribution of PET/CT and bone scan findings in rela-
tion to the final diagnosis
*, Positive findings on both serum ALP and bone scan.
PPV, positive predictive value; NPV, negative predictive value, FDG PET/
CT, fluoro-D-glucose positron emission tomography computed tomog-
raphy; ALP, alkaline phosphatase.
Sensitivity Specificity Accuracy NPV PPV
FDG PET/CT 93.3%  94.1% 93.4% 75.7%  98.6%
(28/30) (143/152) (171/182) (28/37) (143/145)
Bone scan 93.3%  44.1%  52.2% 24.7% 97.1%
(28/30) (67/152) (95/182) (28/113) (67/69)
p 1.000 <0.001 <0.001
Serum ALP 26.7%  94.1% 83.0% 47.1% 86.7%
(8/30) (143/152) (151/182) (8/17) (143/165)
Serum ALP+  26.7% 97.3% 85.7% 66.7%  87.1%
bone scan* (8/30) (148/152) (156/182) (8/12) (148/170)
Table 4. Sensitivity, specificity, and accuracy of PET/CT, bone
scan, and serum ALP concentration
PET/CT, positron emission tomography computed tomography.Bone scan
The BS sensitivity was 93.5%, specificity was 44.1%, posi-
tive predictive value was 24.7%, negative predictive value was
97.1%, and accuracy was 52.2% (Table 4). The sensitivity of
BS was equal to that of PET/CT. The false negative rates of
PET/CT, and BS were identical at 6.7% in two patients for
each modality. PET/CT missed 6.7% (two patients) of all
bone metastasis patients, all of whom had a positive BS.
Serum ALP concentration
The mean value of serum ALP concentration was higher in
patients with bone metastasis than in patients without bone
metastasis. In lung cancer patients, the mean serum concen-
tration of ALP was 103.3±60.0 IU/L in patients with bone
metastasis and 78.5±23.1 IU/L in patients without bone
metastasis (p=0.02). The BS complemented with serum alka-
line phosphatase concentration sensitivity was 26.7%, speci-
ficity was 97.3%, positive predictive value was 66.7%, neg-
ative predictive value was 87.1%, and accuracy was 85.7%
(Table 4).
Accuracy and agreement between diagnostic modalities
of bone metastasis
The McNemar comparison test showed that the specificity
and accuracy were significantly higher for PET/CT than for
BS (p<0.001). The accuracy was also higher for PET/CT than
for serum ALP concentration (p=0.002). BS complemented
with serum ALP concentration gave no additional gain in
sensitivity over PET/CT, but the specificity value was, at least,
equal to that of PET/CT (p=0.26) (Table 3, 4).
The κ statistics were calculated for the three modalities. The
κ value was 0.19 between PET/CT and bone scan, 0.03 bet-
ween BS and serum ALP concentration, and 0.15 between
serum ALP concentration and PET/CT. The low κ values sug-
gested poor agreement between the three modalities (Table 5).
DISCUSSION
Studies of bone metastasis detection show that PET is sig-
nificantly more accurate than BS in detecting various malig-
nancies (e.g., prostate, breast, head and neck, and lung) (7-15).
We used FDG PET/CT instead of FDG PET. Several data
from other studies suggest that PET/CT is more accurate in
detecting tumors using 18F-FDG as the tracer than using
99m-Tc-polyphosphonates (16, 17). Several studies of bone
metastasis have used PET with 18F-fluoride, a bone-imaging
agent (nonspecific bone tracer). The uptake of the fluoride
ion is two-fold higher than that of 99m-Tc-polyphosphonates
(18). Schirrmeister and colleagues compared 99m-Tc-MDP
BS and 18F-NaF PET in the diagnosis of bone metastasis (19).
PET was more sensitive (91.6%) than BS (41.7%) in detect-
ing both osteolytic and osteoblastic lesions. Even-Sapir and
colleagues reported that 18F-fluoride PET/CT is both sensi-
tive and specific in detecting lytic and sclerotic malignant
lesions. In their study, the diagnostic accuracy was 88% for
PET and 100% for PET/CT (p<0.05), and the specificity was
56% for PET and 88% for PET/CT (not significant) (9, 18).
The authors of these studies attributed the better accuracy
of PET/CT compared with PET to better spatial resolution
because PET/CT allows the exclusion of many benign dis-
eases, such as degenerative bone diseases, fractures, and in-
flammation, from the diagnosis of bone metastasis. In addi-
tion, some malignant lesions can be overlooked by PET; for
example, some lytic bone metastasis can be detected only by
PET/CT because of increased uptake at the margins of the
lytic zone.
In a study of 110 patients with lung cancer, Bury and col-
leagues reported that FDG PET was as sensitive as, but had
better specificity than, BS (8). Cheran and colleagues report-
ed a significantly greater accuracy in FDG PET (95%) than
in BS (90%) when equivocal BS results were excluded from
the analysis, and reported a significantly greater sensitivity
of PET (91%) than BS (63-75%) (7). We found a 93.3% sen-
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95% CI κ p
FDG PET/CT and bone scan 0.19 0.10 to 0.28 0.000 
Bone scan and serum ALP 0.03 -0.03 to 0.09 0.448
Serum ALP and FDG PET/CT 0.15 -0.01 to 0.31 0.025
Table 5. Agreement between diagnostic tools
*, Bury and colleagues used PET with fluoride as a tracer, Cheran and
colleagues used FDG PET, and we used FDG PET/CT instead of PET;
� , This variable range was attributed to equivocal findings of bone scan
interpretation.
PET, positron emission tomography.
Bury et al. Cheran et al. Present study*
Number of patients   43/110  104/257  56/182 
with distant metastasis  (39%) (40%) (31%)
PET
Sensitivity 90% 91% 93.30%
Specificity 98% 96% 94.10%
Positive predictive value 90% 85% 75.70%
Negative predictive value 98% 97% 98.60%
Accuracy 96% 95% 93.40%
Bone scan
Sensitivity 90% 63-75%
� 93.30%
Specificity 61% 72-95% 44.10%
Positive predictive value 35% 78-92% 66.70%
Negative predictive value 96% 90-93% 87.10%
Accuracy 66% 90% 52.20%
Table 6. Comparison with data from previous studies
FDG PET/CT, fluoro-D-glucose positron emission tomography comput-
ed tomography, ALP, alkaline phosphatase; CI, confidence interval. FDG PET/CT in Bone Metastasis  279
sitivity of PET/CT, which agrees with values of previous stud-
ies (Table 6). We found two patients with lesions with abnor-
mal findings using PET/CT with normal BS finding. Lesions
identified as abnormal in the BS and normal PET/CT find-
ings were all spine lesions in our study (two patients). Because
all lesions showed no increase in 18F-FDG uptake, we were
unable to show that PET/CT was more effective than simple
PET. In our study, 31% of patients had distant metastasis,
but other studies found 39% and 40% of patients with dis-
tant metastasis (7, 8). The positive predictive value of PET/
CT in our study was thus lower than that of PET in previ-
ous studies because previous studies enrolled more patients
with bone metastases. 
One study compared the detection of bone metastasis in
18F-fluoride and 18F-FDG PET (20). Both 18F-fluoride, as a
nonspecific bone tracer, and 18F-FDG, as an agent to image
altered tumor metabolism, have potential roles in the man-
agement of patients with skeletal metastasis, but no direct
comparison has been reported. In a prospective study, Hoege-
rle and colleagues used a combined FDG and fluoride PET
scan as an advanced metabolic imaging approach to evalu-
ate cancer (21). Seventy-eight percent with positive 18F-flu-
oride PET findings and 88% with positive fluoride and FDG
combination PET findings were confirmed with bone meta-
stasis by morphologic imaging (CT, MRI). However, the im-
provement from 78% in 18F-fluoride PET-diagnosed patients
to 88% in the combined study group was not significant.
Considering that most studies involved FDG PET and node
staging of lung cancer (3), bone metastasis evaluation using
only 18F-fluoride PET is not preferable. More studies are need-
ed to compare PET/CT and PET, especially when 18F-FDG
is used as the tracer in diagnosing bone metastasis.
Ebert and colleagues reported 33.3% sensitivity and 97.5%
specificity of ALP concentration in diagnosing bone metas-
tasis (2). These results agree with our data. Although the
accuracy was 83%, poor agreements among three diagnos-
tic tools (FDG PET/CT, BS, and serum ALP) lowered the
diagnostic value in our study. Other studies reported promis-
ing results for bone-specific ALP and newer bone markers
(osteocalcin, urine deoxypyridinoline crosslinks, etc.), but
serum total ALP concentration had a low diagnostic value
for diagnosing metastatic bone disease (2, 22). Some studies
have compared BS and serum ALP concentration in the detec-
tion of metastatic bone lesions (2, 23), although their com-
plementary roles compared with PET/CT have not been stud-
ied. In our study, BS together with serum ALP concentra-
tion had a higher specificity than did PET/CT, although it
was not significant (p=0.26).
In conclusion, although our data did not show a superior
sensitivity of PET/CT over BS in the screening of metastatic
bone lesions, PET/CT had higher specificity and accuracy.
These data suggest that BS can be eliminated in staging work-
up for preoperative patients who need PET/CT for nodal stag-
ing. However, in patients with disseminated disease who do
not need evaluation of nodal staging, BS and the measure-
ment of serum ALP concentration are sufficient for detect-
ing asymptomatic metastatic bone lesions.
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